[6] Aroeira LS, Aguilera A,

Sánchez-Tomero JA, Bajo MA, del Peso G, Jiménez-Heffernan JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: Pathologic significance and potential therapeutic interventions.

Journal of the American Society of Nephrology. 2007;**18**(7):2004-2013

[7] de Sousa-Amorim E, del Peso G, Bajo MA, Alvarez L, Ossorio M, Gil F, et al. Can EPS development be avoided with early interventions? The potential role of tamoxifen—A Single-Center Study. Peritoneal Dialysis International. 2014;**34**(6):582-593

[8] Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimbürger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Peritoneal Dialysis International. 2006;**26**(1):53-63

[9] Wong TY-H, Szeto C-C, Szeto CY-K, Lai K-B, Chow K-M, Li PK-T. Association of ENOS polymorphism with basal peritoneal membrane function in uremic patients. American Journal of Kidney Diseases. 2003;**42**(4):781-786

[10] Numata M, Nakayama M, Hosoya T, Hoff CM, Holmes CJ, Schalling M, et al. Possible pathologic involvement of receptor for advanced glycation end products (RAGE) for development of encapsulating peritoneal sclerosis in Japanese CAPD patients. Clinical Nephrology. 2004;**62**(6):455-460

[11] Shu K-H, Chuang Y-W, Huang S-T, Cheng C-H, Wu M-J, Chen C-H, et al. Association of interleukin-1β gene polymorphism and peritonitis in uremic patients undergoing peritoneal dialysis. Blood Purification. 2011;**32**(3):156-160

[12] Pletinck A, Vanholder R, Veys N, Van Biesen W. Protecting the peritoneal membrane: Factors beyond peritoneal dialysis solutions. Nature Reviews Nephrology. 2012;**8**(9):542-550

[13] Barreto DL, Hoekstra T, Halbesma N, Leegte M, Boeschoten EW, *Preservation of Peritoneal Membrane Structure and Function in Peritoneal Dialysis DOI: http://dx.doi.org/10.5772/intechopen.111586*

Dekker FW, et al. The association of effluent Ca125 with peritoneal dialysis technique failure. Peritoneal Dialysis International. 2015;**35**(7):683-690

[14] Ahmad S, North BV, Qureshi A, Malik A, Bhangal G, Tarzi RM, et al. CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis. European Journal of Clinical Investigation. 2010;**40**(12):1067-1073

[15] del Peso G, Jiménez-Heffernan JA, Selgas R, Remón C, Ossorio M, Fernández-Perpén A, et al. Biocompatible dialysis solutions preserve peritoneal mesothelial cell and Vessel Wall integrity. A case-control study on human biopsies. Peritoneal Dialysis International. 2016;**36**(2):129-134

[16] García-López E, Lindholm B, Davies S. An update on peritoneal dialysis solutions. Nature Reviews Nephrology. 2012;**8**(4):224-233

[17] Dombros NV, Prutis K, Tong M, Anderson GH, Harrison J, Sombolos K, et al. Six-month overnight intraperitoneal amino-acid infusion in continuous ambulatory peritoneal dialysis (CAPD) patients--no effect on nutritional status. Peritoneal Dialysis International. 1990;**10**(1):79-84

[18] Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney International. 2004;**66**(1):408-418

[19] Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MWY, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. JASN. 2012;**23**(6):1097-1107

[20] Nishimura H, Ikehara O, Naito T, Higuchi C, Sanaka T. Evaluation of taurine as an osmotic agent for Peritoneal Dialysis Solution. 2009. DOI: 10.1177/089686080902900216

[21] Du C, Mendelson AA, Guan Q, Dairi G, Chafeeva I, da Roza G, et al. Hyperbranched polyglycerol is superior to glucose for long-term preservation of peritoneal membrane in a rat model of chronic peritoneal dialysis. Journal of Translational Medicine. 2016;**14**(1):338

[22] Kratochwill K, Boehm M, Herzog R, Lichtenauer AM, Salzer E, Lechner M, et al. Alanyl–glutamine dipeptide restores the cytoprotective stress proteome of mesothelial cells exposed to peritoneal dialysis fluids. Nephrology Dialysis Transplantation. 2012;**27**(3):937-946

[23] Bonomini M, Liberato LD, Rosso GD, Stingone A, Marinangeli G, Consoli A, et al. Effect of an l-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: A 4-month, prospective, multicenter randomized trial. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 2013;**62**(5):929-938

[24] Sousa ED, Peso GD, Alvarez L, Ros S, Mateus A, Aguilar A, et al. Peritoneal resting with heparinized lavage reverses peritoneal type I membrane failure. A Comparative Study of the Resting Effects on Normal Membranes: Peritoneal Dialysis International. 2014. DOI: 10.3747/pdi.2013.00286

[25] Effect of renin–angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients - JING - 2010 - Nephrology - Wiley Online Library. DOI: 10.1111/j.1440-1797.2009.01162.x

[26] Effect of Self-administered Intraperitoneal Bemiparin on Peritoneal Transport and Ultrafiltration Capacity

in Peritoneal Dialysis Patients with Membrane Dysfunction. A Randomized, Multi-centre Open Clinical Trial | Nephrology Dialysis Transplantation | Oxford Academic. Available from: https://academic.oup.com/ndt/ article/27/5/2051/1838368 [Accessed: January 28, 2021]

[27] Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross M-L, et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. Journal of American Society Nephrology. 2011;**22**(5):914-926

[28] Kakuta T, Tanaka R, Satoh Y, Izuhara Y, Inagi R, Nangaku M, et al. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney International. 2005;**68**(3):1326-1336

[29] Cyclooxygenase-2 Mediates Dialysate-Induced Alterations of the Peritoneal Membrane | American Society of Nephrology. Available from: https:// jasn.asnjournals.org/content/20/3/582 [Accessed: January 27, 2021]

[30] Fukuyama J, Ichikawa K, Hamano S, Shibata N. Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. European Journal of Pharmacology. 1996;**318**(2):327-332

[31] The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells from Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis - Fan - 2016 - STEM CELLS Translational Medicine - Wiley Online Library. DOI: 10.5966/sctm.2015-0001
